SaidR.BeydounMD

Neurology • Los Angeles, CA

Neuromuscular Medicine, Neurophysiology, Pain Medicine

Professor of Neurology, USC School of Medicine

Join to view full profile

Dr. Beydoun is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Beydoun's full profile

Already have an account?

Office
1520 San Pablo St
Ste 3000
Los Angeles, CA 90033
Phone+1 323-442-5710

Fax+1 323-442-5736

Education & Training

University of Southern California/Los Angeles General Medical Center (USC/LA General)Fellowship, Pain Medicine, 1985 - 1986
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Neurology, 1983 - 1984
University of Miami/Jackson Health SystemResidency, Neurology, 1981 - 1983
American University of Beirut Faculty of MedicineClass of 1980

Certifications & Licensure

CA State Medical License 1983 - 2026
FL State Medical License 1982 - 1998
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Clinical Neurophysiology
American Board of Psychiatry and Neurology Neuromuscular Medicine
American Board of Psychiatry and Neurology Pain Medicine

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Start of enrollment: 2006 Jun 01
Completed
Phase 3
Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy Start of enrollment: 2008 Aug 22
Completed
Phase 3
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Start of enrollment: 2008 Oct 01
Terminated
Phase 2
The Evaluation of Belimumab in Myasthenia Gravis (MG) Start of enrollment: 2013 Apr 01
Completed
Phase 2
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Start of enrollment: 2012 Mar 01
Completed
Phase 3
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) Start of enrollment: 2013 Dec 01
Completed
Phase 3
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Start of enrollment: 2014 Jul 30
Completed
Phase 3
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis Start of enrollment: 2015 May 01
Completed
Phase 2
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis Start of enrollment: 2014 Nov 12
Completed
Phase 3
Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Start of enrollment: 2015 Aug 01
Withdrawn
Phase 2
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Start of enrollment: 2016 Dec 30
Completed
Phase 2
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis Start of enrollment: 2017 May 15
Completed
Phase 2
Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2017 Jun 22
Terminated
Phase 2, Phase 3
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Start of enrollment: 2018 Apr 18
Completed
Phase 3
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) Start of enrollment: 2018 Jun 11
Terminated
Phase 3
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Start of enrollment: 2018 Aug 22
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Impact of the updated chronic inflammatory demyelinating polyneuropathy guideline on everyday clinical practice.
Suraj Muley, Said R Beydoun
Therapeutic Advances in Neurological Disorders. 2023-01-01
8 citations
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myast...
James F Howard Jr, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric
Frontiers in Neurology. 2023-01-01
2 citations
Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3...
John D Markman, Thomas J Schnitzer, Serge Perrot, Said R Beydoun, Seiji Ohtori
Pain and Therapy. 2022-12-01

Journal Articles

Late-Onset Hereditary Tranthyretin Amyloidosis in Two Patients with Acquired Demyelinating Features
Nazila Rad, Said R Beydoun, US Neurology, 11/6/2018
The Challenge of Distinguishing POEMS from Chronic Inflammatory Demyelinating Polyneuropathy-Importance of Early Recognition and Diagnosis of POEMS
Francis Chow, Leila Darki, Said R Beydoun, US Neurology, 11/6/2018
Edaravone in Amyotrophic Lateral Sclerosis - Lessons from the Clinical Development Program and the Importance of a Clinical Trial Design
Said R Beydoun, Jeffrey Rosenfeld, US Neurology, 2018
Chronic Inflammatory Demyelinating Polyradiculoneuropathy 101-Pitfalls and Pearls of Diagnoses and Treatment
Said R Beydoun, Thomas H Brannagan III, Peter Donofrio, Carol Lee Koski, Eric Lancaster, US Neurology, 2017
Delayed Appearance of Conduction Block in Multifocal Motor Neuropathy
Leila Darki, Said R Beydoun, US Neurology, 2017
Differentiating Multifocal Motor Neuropathy from Entrapment Neuropathy-A Diagnostic Challenge
Richard A Rison, Said R Beydoun, US Neurology, 2016
Different Presentations of Myelopathy - A Case Series
Krishna Pokala, David Girard, Said R Beydoun, US Neurology, 2016
Join now to see all